Case Report

Decreased *Clostridium* Abundance after Electroconvulsive Therapy in the Gut Microbiota of a Patient with Schizophrenia

Misako Kanayama, Maiko Hayashida, Sadayuki Hashioka, Tsuyoshi Miyaoka, and Masatoshi Inagaki

Department of Psychiatry, Shimane University of Medicine, 89-1 Enyacho, Izumo 6938501, Japan

Correspondence should be addressed to Misako Kanayama; misakoka@med.shimane-u.ac.jp

Received 13 November 2018; Revised 17 January 2019; Accepted 11 February 2019; Published 25 February 2019

1. Introduction

Schizophrenia is a severe psychiatric disorder, but its pathophysiology and therapeutic mechanisms remain unclear. In recent years, gut microbiota's influence on various biological functions and disease pathogenesis [1–3], including those of schizophrenia [4–7], has been investigated. Many studies have illustrated that gut microbiota interacts with the immune system, regulates brain activity, and influences behavioral processes. However, findings on gut microbiota characteristics in patients with schizophrenia have been less consistent [5].

Several bacterial genera, including *Clostridium*, *Bacteroides*, and *Lactobacillus*, have attracted attention as research targets. Three previous studies found that *Clostridium* is more abundant in the gut microbiota of patients with schizophrenia compared with those of healthy individuals [8–10], although one study reported the opposite result [11]. One report demonstrated that *Clostridium* abundance declined in patients with schizophrenia after the patients received drug treatment [9]. However, no study has investigated the changes in the gut microbiota before and after electroconvulsive therapy (ECT) in patients with schizophrenia. Herein, we report a case of a patient with schizophrenia treated with ECT and the changes in her gut microbiota after ECT.

2. Case Presentation

A 59-year-old woman was diagnosed with schizophrenia at 17 years of age and had been taking antipsychotic drugs since the diagnosis. She had no history of alcohol consumption or drug abuse. At age 57, she was admitted to another mental hospital after entering a catatonic state that was resistant to several antipsychotic drugs and benzodiazepines. She experienced delusions, hallucinations, grossly disorganized and catatonic behavior, and negative symptoms lasting more than 6 months. She showed no symptoms of organ disease on blood tests, neurological tests, or magnetic resonance...
imaging (MRI) of the head. Thus, we diagnosed her with schizophrenia based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5). At her one-year follow-up after ECT, she had no symptoms indicating organ disease, and her diagnosis remained the same. In addition, she exhibited stupor, catatopy, waxy flexibility, negativism, mannerism, stereotypy, agitation not influenced by external stimuli, and echolalia. Thus, we diagnosed her with catatonia per the DSM-5. No EEG and CSF analysis had been performed. Therefore autoimmune NMDA-Rencephalitis and potentially associated viral infections (e.g., Herpes; Influenza) had not been sufficiently ruled out.

She had been taking 9 mg of risperidone daily for 2 years for her severe symptoms without exothermic reactions or increased creatine phosphokinase (CPK); thus, she continued taking risperidone for her severe symptoms. Clozapine could not be administered because her white blood cell count was too low. No other symptoms of cytopenia, infection, or blood disorders were observed. She had no symptoms of organ disease. We suspected that the antipsychotic drugs were affecting her blood cell counts, but we determined that the cell counts were not clinically significant. Her white blood cell counts did not change, even after receiving ECT.

In addition, she had been taking 1.2 g magnesium oxide and 36 mg sennoside daily for constipation for many years during and after ECT. Her laxative remained unchanged. We did not exclude organ digestive diseases using advanced methods such as endoscopy. Instead, we judged clinically that her constipation were due to adverse effects from the drugs and her lifestyle habits. She had no intestinal obstruction or diseases that caused outright autonomic nervous abnormalities.

The patient's feces were sampled 1 month after admission (on the day before administering ECT) and 2 days after the final ECT session. The feces were collected promptly after defecation and stored at below -20°C until analysis. The bacterial composition of the gut microbiota was analyzed using the terminal restriction fragment length polymorphism method (Techno Suruga Labo Co. Ltd., Shizuoka, Japan). Her psychiatric symptoms were also evaluated using the Brief Psychiatric Rating Scale (BPRS) and the Bush-Francis Catatonia Rating Scale (BFCRS) [12]. We assumed that she lacked the capacity to provide informed consent; therefore, her father provided written informed consent for both publishing and this protocols approved by the Ethics Committee of Shimane University Hospital (no. 20160727-1).

We performed 14 ECT sessions (three times per week) in accordance with the revised edition of the Electrical Convulsion Therapy (ECT) Recommendation of the Department of Neuropsychiatry of Japan, which was created by translating the American Psychological Association (APA) treatment guidelines. The number of ECT sessions was reevaluated at the 10th session and continued. We used thiopental or ketamine as an anesthetic and stopped her breakfast on the morning of the ECT. After ECT, her BPRS score decreased from 83 to 65, and her BFCRS score decreased from 51 to 28. In addition, her gut microbiota differed before and after ECT. Clostridium abundance decreased from 86.5% to 72.5%, while Lactobacillus increased from 1.2% to 5.5%, and Bacteroides increased from 9.1% to 31.5%.

3. Discussion

In this case, we observed a decrease in the Clostridium abundance and increases in the Bacteroides and Lactobacillus abundances after ECT. Thus, compared with previous pharmacological studies on gut microbiota, both ECT and antipsychotic drug treatments appear to decrease the amount of Clostridium in the gut microbiota of patients with schizophrenia. At least three studies [8–10] have reported that Clostridium was more abundant in the gut microbiota of patients with schizophrenia than in those of healthy individuals. Our report is the first to report the gut microbiota of a patient with schizophrenia receiving ECT. Our results were consistent with those of Yuan et al. (2018), who published the only study to examine changes in the gut microbiota before and after a 24-week risperidone treatment in patients with schizophrenia [9].

We also observed that Lactobacillus and Bacteroides increased after ECT. However, no consensus exists on the differences in these floras among healthy individuals or how they change after antipsychotic treatment [9–11].

Given the consistent results regarding the reduction in Clostridium after both pharmacotherapy and ECT, we considered three possibilities. First, ECT ameliorated the psychiatric symptoms, and the Clostridium abundance decreased because of the psychiatric symptom relief. Second, ECT ameliorated the psychiatric symptoms and independently reduced the Clostridium abundance. Third, ECT directly reduced the Clostridium abundance by altering the autonomic nervous system and/or immune system, and this reduction in Clostridium ameliorated the psychiatric symptoms.

Though there is no definite consensus, we are interested in the third hypothesis. Several studies support the third hypothesis that the mechanisms of the ECT’s therapeutic effects are related to the autonomic nervous [13, 14] and immune systems [15–17]. Several studies have also reported that the gut microbiota may influence both the autonomic nervous and immune systems by increased intestinal permeability, an intestinal catecholamine receptor, or various other phenomena such as antigen-antibody reactions [4–6, 18, 19]. Investigations of these hypotheses might help clarify schizophrenia’s pathophysiology and therapeutic mechanisms, for example, via immunological, autonomic, or other mechanisms or pathophysiologies; thus, future research is needed.

This case report has some limitations. First, the patient’s diet may have influenced the results. However, her diet changed only slightly from the time of her hospital admission at age 55 to the final ECT sessions. Her eating [20, 21], bowel, and exercise [22] habits remained the same before and after ECT based on her medical records regarding diet contents and amount, time and form of defecation, and amount of activity during the day, excluding that she did not eat breakfast on the mornings she had ECT. In addition, some
reports suggest that the variation in gut microbiota due to diet is relatively small [20, 23]. However, the influence of the diet remains unclear, and more research is needed.

Second, the drugs that the patient was taking may have affected the results. However, her medication details remained the same before and after ECT (for two years). In addition, as for anesthesia, how the anesthetic affects gut microbiota is unknown. In this case, since no convulsions occurred with the first anesthetic used, the physician changed the anesthetic to ketamine. In Japan, propofol is used as the first anesthetic, but this drug increases the seizure threshold. In cases where high seizure thresholds are a problem, the anesthetic is rather small [20, 23]. However, the influence of the diet remains unclear, and more research is needed.

Because previous studies have reported that Clostridium abundance decreases after drug therapy, and because this might be related to schizophrenia’s therapeutic mechanisms and/or pathophysiology. Since this was a case report, this should be clarified through further research.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors thank all doctors and staff of the Department of Psychiatry, Shimane University of Medicine, for their help with the ECT. The authors also thank Traci Raley, MS, ELS, from Edanz Group (www.edanzediting.com/ac), for editing a draft of this manuscript.

References

[1] J. K. Goodrich, J. L. Waters, A. C. Poole et al., “Human genetics shape the gut microbiome,” Cell, vol. 159, no. 4, pp. 789–799, 2014.

[2] P. J. Turnbaugh, R. E. Ley, M. Hamady, C. M. Fraser-Liggett, R. Knight, and J. I. Gordon, “The human microbiome project,” Nature, vol. 449, no. 7164, pp. 804–810, 2007.

[3] J. Qin, R. Li, J. Raes et al., “A human gut microbial gene catalogue established by metagenomic sequencing,” Nature, vol. 464, no. 7285, pp. 59–65, 2010.

[4] E. G. Severance, K. L. Gressitt, A. Alaeddin et al., “IgG dynamics of dietary antigens point to cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia,” Brain, Behavior, and Immunity, vol. 44, pp. 148–158, 2015.

[5] E. G. Severance, E. Prandovszky, J. Castiglione, and R. H. Yolken, “Gastroenterology issues in schizophrenia: why the gut matters,” Current Psychiatry Reports, vol. 17, no. 5, p. 27, 2015.

[6] T. T. Nguyen, T. Kosciolek, L. T. Eyler, R. Knight, and D. V. Jeste, “Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder,” Journal of Psychiatric Research, vol. 99, pp. 50–61, 2018.

[7] T. G. Dinan, Y. E. Borre, and J. F. Cryan, “Genomics of schizophrenia: Time to consider the gut microbiome?,” Molecular Psychiatry, vol. 19, no. 12, pp. 1252–1257, 2014.

[8] Y. Shen, J. Xu, Z. Li et al., “Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study,” Schizophrenia Research, vol. 197, pp. 470–477, 2018.

[9] X. Yuan, P. Zhang, Y. Wang et al., “Changes in metabolism and microbiota after 24-week risperidone treatment in drug naive, normal weight patients with first episode schizophrenia,” Schizophrenia Research, 2018.

[10] Y. He, T. Kosciolek, J. Tang et al., “Gut microbiome and magnetic resonance spectroscopy study of subjects at ultra-high risk for psychosis may support the membrane hypothesis,” European Psychiatry, vol. 53, pp. 37–45, 2018.

[11] T. T. Nguyen, T. Kosciolek, Y. Maldonado et al., “Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects,” Schizophrenia Research, 2018.

[12] G. Bush, M. Fink, G. Petrides, F. Dowling, and A. Francis, “Catatonia. I. Rating scale and standardized examination,” Acta Psychiatrica Scandinavica, vol. 93, no. 2, pp. 129–136, 1996.

[13] D. M. Dhossche, “Vagal intimations for catatonia and electroconvulsive therapy,” Journal of ECT, vol. 30, no. 2, pp. 111–115, 2014.

[14] S. Laye, R. M. Bluthe, S. Kent et al., “Subdiaphragmatic vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to peripheral LPS,” American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol. 268, no. 5, pp. R1327–R1331, 1995.

[15] B. J. Müller, P. Buckley, W. Seabolt, A. Mellor, and B. Kirkpatrick, “Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects,” Biological Psychiatry, vol. 70, no. 7, pp. 663–671, 2011.

[16] E. M. van Buel, K. Patas, M. Peters, F. J. Bosker, U. L. M. Eisel, and H. C. Klein, “Immune and neurotrophin stimulation by electroconvulsive therapy; is some inflammation needed after all?” Translational Psychiatry, vol. 5, p. e609, 2015.

[17] P. B. Rosenquist, B. Miller, and A. Pillai, “The antipsychotic effects of ECT: A review of possible mechanisms,” Journal of ECT, vol. 30, no. 2, pp. 125–131, 2014.

[18] P. P. E. Freestone, S. M. Sandrini, R. D. Haigh, and M. Lyte, “Microbial endocrinology: how stress influences susceptibility to infection,” Trends in Microbiology, vol. 16, no. 2, pp. 55–64, 2008.

[19] M. T. Bailey and J. F. Cryan, “The microbiome as a key regulator of brain, behavior and immunity: Commentary on the 2017 named series,” Brain, Behavior, and Immunity, vol. 66, pp. 18–22, 2017.

[20] G. D. Wu, J. Chen, C. Hoffmann et al., “Linking long-term dietary patterns with gut microbial enterotypes,” Science, vol. 354, no. 6052, pp. 105–108, 2011.

[21] P. W. O’Toole and I. B. Jeffery, “Gut microbiota and aging,” Science, vol. 350, no. 6265, pp. 1214-1215, 2015.
[22] S. F. Clarke, E. F. Murphy, and O. O’Sullivan, “Exercise and associated dietary extremes impact on gut microbial diversity,” *Gut*, vol. 63, no. 12, pp. 1913–1920, 2014.

[23] E. K. Costello, C. L. Lauber, M. Hamady, N. Fierer, J. I. Gordon, and R. Knight, “Bacterial community variation in human body habitats across space and time,” *Science*, vol. 326, no. 5960, pp. 1694–1697, 2009.

[24] B. Getachew, J. I. Abee, R. S. Schottenfeld, A. B. Csoka, K. M. Thompson, and Y. Tizabi, “Ketamine interactions with gut-microbiota in rats: relevance to its antidepressant and anti-inflammatory properties,” *BMC Microbiology*, vol. 18, no. 1, p. 222, 2018.